Guangzhou Lbp Medicine Science&Technology688393.SHValuation Analysis

As of Oct 19, 2026, Guangzhou Lbp Medicine Science&Technology (688393.SH) trades at a negative P/E (-54.46x, due to a recent net loss), P/B of 1.62x, P/S of 5.36x, and a dividend yield of 0.51%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 23rd percentile over the trailing 10Y window (vs. 43rd percentile over 3Y); P/S sits at the 40th percentile over the trailing 10Y window (vs. 46th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 25th percentile within its industry and the 26th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.51%, ranking at the 35th percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Guangzhou Lbp Medicine Science&Technology operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.